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Transition metal-free synthesis of a known intermediate in the 
formal synthesis of (-)-steganacin 
David Augros, Boubacar Yalcouye, Sabine Choppin, Matthieu Chessé, Armen Panossian* and 
Frédéric R. Leroux* 
Abstract: The formal synthesis of both enantiomers of a natural 
axially chiral biaryl, steganacin is reported. The previously developed 
atropo-diastereoselective coupling of an aryne and an aryllithium (the 
'ARYNE coupling') allows for this synthesis. In each step, the axial 
configuration of the biaryl could be maintained. The key intermediate 
of literature was accessed without using transition metals, 
demonstrating the interest of the ARYNE coupling as a complement 
or an alternative to transition metal-catalyzed couplings. 
Introduction 
(-)-Steganacin (2) (Scheme 1) is a known chiral biaryl-based 
natural product, which showed potent antimicrotubule in vivo 
activity against mice cancer cell lines and in vitro activity against 
human cancer cell lines, but did not find any medicinal application; 
however, the early interest for this potential anticancer agent as 
well as the synthetic challenge explain why (-)-steganacin and its 
one-step precursor (-)-steganone (1), their enantiomers and 
racemates have been the target of many new synthetic 
methods.[1] We already described a palladium-catalyzed atropo-
diastereoselective Suzuki-Miyaura coupling as a key step to 
prepare a known synthetic intermediate (3) initially described by 
Harayama, Abe et al.[1ab,1ac] in the formal synthesis of (-)-
steganone.[2] In the present paper, we report on an alternative 
transition metal-free, lithium-based synthesis of Harayama and 
Abe's intermediate 3, in view of a transition metal-free total 
synthesis of (-)-steganacin or its derivatives. Indeed, despite their 
versatile use as catalysts in all sorts of reactions, transition metals 
might be a concern especially in the pharmaceutical industry, 
where recommended levels in active pharmaceutical ingredients 
are very low (permitted daily exposure of patients to palladium: 
100 μg/day for oral doses, 10 μg/day for parenterally administered 
drugs, 1 μg/day by inhalation).[3a,3b] In comparison, the respective 
permitted daily exposures of patients to lithium are of 560, 280 
and 25 μg/day,[3b] which, given the atomic mass of both elements, 
favours lithium even if it is used in stoichiometric amount while 
palladium is used in catalytic quantities. Accordingly, the use of 
transition metals in late-stage synthesis is problematic and 
requires efficient, but costly, removal of trace metals (e.g. 
scavenging agents or nanofiltration).[4] Additionally, the price per 
tonne of palladium, ca. 2000–3000 times more expensive than 
lithium, has also to be taken in consideration. Consequently, 
transition metal-free syntheses might offer an appealing solution. 
We recently described the coupling between an in situ-generated 
aryne and an aryllithium nucleophile bearing a chiral oxazolinyl 
group ortho to lithium; the design of the coupling partners was 
directed towards the formal synthesis of (-)-steganacin as a model 
target. Although very moderate selectivity was achieved, we 
showed that the desired biaryl 4 could be produced with a 
satisfying 67% yield, given the steric bulk surrounding the newly 
formed, tetra-ortho-substituted aryl-aryl bond, and that both 
atropo-diastereoisomers could be separated by column 
chromatography and their absolute configuration determined by 
X-ray diffraction crystallography.[5] Having created the biaryl 
backbone of (-)-steganacin, we had now to transform it into 
intermediate 3, without using transition metals.  
 
Scheme 1. Planned strategy for the formal synthesis of (-)-steganacin. 
Results and Discussion 
In order to do so, three kinds of transformations had to be carried 
out, independently of their order: 1) double desilylation, 2) 
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conversion of iodine into a formyl group, 3) reduction of the 
oxazoline into an alcohol. Starting from iodo-to-formyl conversion 
by halogen/lithium exchange appeared to be unfruitful (Scheme 
2). Indeed, addition of 1 equiv. of butyllithium in THF at -78 °C to 
4b (S,aS)—as a model in place of the desired 4a (S,aR)— 
followed by trapping with DMF after 30 minutes only led to the 
undesired fluorenone 5[5] in 69% yield. When reducing the time 
before DMF addition to 5 minutes, we surprisingly recovered 50% 
of starting material, i.e. with untouched iodine, while 5 was still 
formed in 39% yield. The recovery of unreacted iodobiphenyl can 
be ascribed to the high steric bulk around iodine, decreasing its 
reactivity. Anyway, in both cases, no desired aldehyde was 
obtained after work-up. The fluorenone formation at the detriment 
of the trapping by DMF was coherent with our previous 
findings.[5,6] Indeed, cyclisation of the biaryllithium intermediate is 
favored over trapping with an electrophile when the latter is either 
slowly reacting or not already present in the reaction medium for 
in situ trapping of the forming biaryllithium. 
 
Scheme 2. Attempts of iodine/lithium exchange and trapping with DMF on 
iodobiaryl 4b. 
Consequently, we rather decided to perform the formylation as a 
last step, and to investigate on the double desilylation of the biaryl 
moiety. This transformation was critical from a synthetic point of 
view, insofar as both TMS groups had to be removed efficiently 
and without epimerization of the chiral axis. Therefore, we wished 
to perform the protodesilylation at low temperature if possible. We 
again started first with a model bis(trimethylsilylated) biaryl, 6 
(Scheme 3), that we already described.[5] and treated it with TFA, 
a known desilylating agent of electron-rich aromatic rings.[7] The 
reaction proceeded well in the presence of excess TFA at room 
temperature, although a long reaction time was required to fully 
remove the TMS group in position 6. Indeed, the latter is quite 
hindered by the dimethoxyphenyl ring, as observed by 1H NMR 
where TMS-6 is shielded by 0.34 ppm with regard to TMS-3 due 
to the anisotropy cone generated by the aforementioned 
dimethoxyphenyl (Scheme 3). Since the TFA-promoted proto-
desilylation —by electrophilic aromatic substitution— requires 
tetragonalization of the ipso carbon, the higher steric hindrance 
around carbon-6 explains that it is less prone to the latter change 
of geometry. In the end, the reaction afforded the totally 
desilylated product 7 in 87% yield after 72 h of reaction at 25 °C 
(Scheme 3). 
 
Scheme 3. Double protodesilylation of model compound 6. 
However, when applying these conditions to the (S,aS) 
diastereomer 4b, where the TMS-substituted carbon-6 is much 
more congested than in 6, only the mono-desilylated product 8 
was obtained in 61% yield, nevertheless with retention of axial 
stereo-enrichment (Scheme 4). Apart from the characteristic 
shielded 1H NMR chemical shift of the untouched TMS group, the 
structure of 8 was confirmed by NOESY, showing a correlation 
between the signals of the TMS and of the methoxy groups, as 
well as another between the signals of the TMS and of the 
aromatic proton located ortho to the oxazoline. When other 
conditions or other acids (HCl, H2SO4) were tried, complex 
mixtures were obtained, from which biphenylcarboxylic acids, 
coming from hydrolysis of the oxazoline moiety, could sometimes 
be identified. On the other hand, using a 1M TBAF solution in THF 
to accomplish the protodesilylation —via a different, anion-based 
mechanistic pathway— revealed completely ineffective. 
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Scheme 4. Single and double protodesilylation of both atropo-isomers of 4. 
Eventually, we succeeded in deprotecting both silylated carbons 
of 4b and 4a by employing TBAF-trihydrate in DMF at 50 °C for 
2.5 days. Gratifyingly, no erosion of diastereomeric ratio was 
observed in product 9, even at this temperature and reaction time, 
and quantitative yields were obtained. More gratifyingly, we later 
found out that the same reaction was complete after 30 min, even 
at room temperature (Scheme 4). In view of further 
transformations towards (-)-steganacin or analogues, it is 
noteworthy that the desilylations can be performed stepwise with 
first TFA, and then TBAF•3H2O/DMF, making this sequence an 
interesting tool for controlled deprotection. 
Then, to reduce the oxazoline of 9a, we first hydrolyzed it under 
conditions similar to Meyers',[8] using TFA in a THF/water mixture, 
at room temperature to prevent potential epimerization of the 
chiral axis (Scheme 5). The crude biaryl ester with a pendant 
ammonium function was then treated with reducing agents. 
Lithium aluminum hydride was effective, but also reduced the 
carbon-iodine bond. We therefore turned to lithium borohydride in 
combination with methanol, which, at first, gave irreproducible 
results. We soon realized that this was related to the basic work-
up of the reaction of 9a, which was critical as it could either afford 
the ammonium 10a, the corresponding amine 11a, or a mixture of 
both. Indeed, when the hydrolysis of the oxazoline was followed 
by simple washing of the organic layer with saturated NaHCO3 
and extraction with ether, either 10a or a mixture of 10a and 11a, 
where ammonium 10a was largely major, were obtained. On the 
other hand, when the reaction mixture was quenched with 
saturated NaHCO3 until evolution of CO2 had ceased, then 
extracted with diethyl ether, amine 11a was the sole product, as 
shown by the absence of fluorine signals in 19F NMR of the crude. 
Then, as implied above, the nature of the ester to be reduced 
(10a/11a) proved influential, as 10a and 11a did not behave 
similarly upon treatment with LiBH4/MeOH[9]. While the crude 
ammonium 10a afforded the desired alcohol 12a in 69% yield, 
amine 11a led to a mixture of 12a (minor) and amide 13a (major) 
by rearrangement of the aminoalkyl ester. Accordingly, to prevent 
formation of the amide 13a and to increase the yield of the alcohol 
12a, we first reacted the crude 11a with the borane-THF complex 
and then treated the mixture with LiBH4/MeOH. We reasoned 
indeed that borane would coordinate to the free amine, preventing 
it from attacking the ester. This strategy proved efficient, and we 
finally obtained 91% yield of alcohol 12a from oxazoline 9a 
(Scheme 5). We then quantitatively protected the compound as a 
silyl ether 14a, of which the enantiomeric ratio was measured by 
chiral HPLC analysis to be higher than 99:1, confirming retention 
of axial stereoenrichment (Scheme 6). The opposite atropo-
isomers 12b and 14b were also synthesized from 9b with similar 
yields (Scheme 5 and Scheme 6). 
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Scheme 5. Reduction of the oxazoline moiety. 
 
Scheme 6. Protection-iodine/lithium exchange-formylation sequence. 
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Finally, the most critical step was the iodine/lithium exchange 
followed by trapping with DMF, which ought to proceed without 
epimerization of the biaryllithium intermediate to afford the 
desired aldehyde 3. We thus carried out the reaction at low 
temperature (-100 °C) and with tert-butyllithium as the base for a 
clean halogen/metal exchange. Here as well (see Scheme 2), the 
usual number of equivalents of base (2 in the case of tBuLi) 
appeared insufficient for an effective conversion of the biaryl 
iodide, as only 8% yield of aldehyde 3 were achieved (Scheme 6). 
In the end, 5 equiv. of tBuLi managed to produce 3 in 85% yield. 
Again, the same strategy was applied to the opposite atropo-
isomer 14b, giving ent-3 with 81% yield. Both enantiomers were 
showed to be enantiopure by chiral HPLC (>99:1 e.r.). 
Conclusions 
In conclusion, we carried out the synthesis of Harayama and 
Abe's intermediate 3 in 9 steps, 22% overall yield, excellent 
control of chirality (>98% e.e., with retention of axial 
stereoenrichment at each stage of the process), and in the 
absence of transition metals (Scheme 7). Interestingly, the 
enantiomer ent-3 of the target compound could be obtained with 
similar efficiency. This transition metal-free synthetic pathway is 
an efficient alternative to Harayama and Abe's synthesis of 3[1ab,ac] 
(10 steps from piperonyl alcohol, 25% overall yield, 83% e.e.) or 
our previous Pd-catalyzed strategy[2] (15 steps from piperonyl 
alcohol, 9% overall yield, 94% e.e.), which both involved 
palladium-promoted steps and stoichiometric chromium-
mediated transformations. The current work enforces the interest 
in heavy metal-free biaryl synthesis applied to the preparation of 
potential pharmaceutically relevant ingredients. 
 
Scheme 7. Formal synthesis of (-)-steganacin. 
Experimental Section 
See the Supporting Information for further information. The preparation of 
compounds 4a, 4b, 5 and 6 was already described.[5] 
5-Bromo-6-(2,6-dimethoxyphenyl)benzo[d][1,3]dioxole (7) 
To a stirred solution of bis(trimethylsilyl)biarylbromide 6 (0.20 g, 0.42 mmol, 
1 equiv.) in dry dichloromethane (9 mL), was added trifluoroacetic acid 
(1.68 mL) at 25 °C. The reaction mixture was stirred for 3 d at 25 °C. The 
mixture was concentrated and the residue was taken up in CHCl3 (40 mL), 
washed with NaHCO3 (40 mL), water (40 mL), then brine (40 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure to afford 
7 as a yellow solid; yield = 0.12 g (0.36 mmol, 87%); Rf = 0.38 
(cyclohexane/CH2Cl2 = 1:1); M.p. = 119-121 °C; ṽ = 294.7, 2902.7, 2838.2, 
1593.4, 1473.5, 1243.0 (C-O), 1098.5 (C-O), 1018.6, 926.4 cm-1; 1H NMR 
(CDCl3, 400 MHz): δ = 7.33 (t, 1 H, 3J = 8.4 Hz, Ar-H), 7.12 (s, 1 H, Ar-H), 
6.72 (s, 1 H, Ar-H), 6.65 (d, 2 H, 3J = 8.4 Hz, Ar-H), 6.00 (s, 2 H, OCH2O), 
3.76 (s, 6 H, OCH3) ppm; 13C NMR (CDCl3, 100 MHz): δ = 157.97 (C), 
147.63 (C), 147.15 (C), 129.53 (CHAr), 128.96 (C), 118.86 (C), 115.78 (C-
Br), 112.67 (CHAr), 111.93 (CHAr), 104.21 (CHAr), 101.79 (OCH2O), 56.16 
(OCH3) ppm; C15H13BrO4 (335.99): calcd. C 53.43, H 3.89; found C 53.27, 
H 4.04. 
(S)-2-(2-(aS)-(6-Iodo-4-(trimethylsilyl)benzo[d][1,3]dioxol-5yl)-3,4,5-
trimethoxyphenyl)-4-isoproyl-4,5-dihydrooxazole (8) 
To a stirred solution of 4b (220 mg, 0.33 mmol, 1 equiv.) in dry 
dichloromethane (4 mL), was added trifluoroacetic acid (1.22 mL, 16.43 
mmol, 50 equiv.) at 25 °C. The reaction mixture was stirred at 25 °C for 16 
h. Saturated aqueous NaHCO3 was added portionwise to the stirred 
mixture until no more carbon dioxide evolution was observed and the 
mixture was extracted thrice with Et2O. The organic layers were combined, 
dried over Na2SO4, filtered and concentrated under vacuum to give the 
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crude, which was purified by column chromatography on silica gel, eluting 
with a cyclohexane/AcOEt gradient to yield 8 as a pale yellow oil; yield = 
120 mg (0.20 mmol, 61%); Rf = 0.21 (cyclohexane/AcOEt = 90:10); [α]D20 
= -2.1 (c = 1.00, CHCl3);  = 2956.2, 2933.0, 1653.9 (C=N), 1589.8, 1398.2, 
1359.3, 1196.8, 1099.2, 1019.5, 839.7 (Si(CH3)3), 765.3, 692.8, 630.6 cm-
1; 1H NMR (CDCl3, 400 MHz): δ = 7.25 (s, 1 H, Ar-H), 7.23 (s, 1 H, Ar-H), 
5.95 (ABq, 2 H, ΔδAB = 0.01, JAB = 1.3 Hz, O-CH2-O), 4.13-4.05 (m, 1 H, 
O-CH2-C), 3.94 (s, 3 H, Ar-OCH3), 3.90 (s, 3 H, Ar-OCH3), 3.88-3.80 (m, 2 
H, O-CH2-C + NCH), 3.72 (s, 3 H, Ar-OCH3), 1.57 (sept.d, 1 H, 3J = 6.6 Hz, 
3J = 6.6 Hz, CHiPr), 0.78 (d, 3 H, 3J = 6.7 Hz, CH3iPr), 0.77 (d, 3 H, 3J = 6.8 
Hz, CH3iPr), -0.07 (s, 9 H, Si(CH3)3) ppm; 13C NMR (CDCl3, 100 MHz): δ = 
162.43 (C=N), 153.03 (C), 152.83 (C), 151.87 (C), 145.65 (C), 144.26 (C), 
139.58 (C), 134.13 (C), 124.30 (C), 122.25(C), 118.14 (CHAr), 108.05 
(CHAr), 100.69 (OCH2O), 91.59 (C-I), 72.77 (NCH), 70.27 (OCH2), 60.68 
(Ar-OCH3), 60.56 (Ar-OCH3), 56.16 (Ar-OCH3), 33.12 (CHiPr), 18.69 
(CH3iPr), 18.61 (CH3iPr), -0.34 (Si(CH3)3) ppm; HRMS ES m/z [M+Na]+ 
calcd. for C22H24INaNO6: 620.0941, found 620.0938. 
(S,aR)- and (S,aS)-2-[2-(6-iodo-2H-1,3-benzodioxol-5-yl)-3,4,5-
trimethoxyphenyl]-4-(propan-2-yl)-4,5-dihydro-1,3-oxazole (9a and 
9b) 
The desired atropo-diastereomer of 4 (1 equiv.) was dissolved in DMF (0.3 
M). Tetrabutylammonium fluoride trihydrate (2.5 equiv.) was added and 
the mixture was stirred for 30 min at RT. The reaction mixture was taken 
up in brine and extracted twice with Et2O. The organic layers were 
combined, washed thrice with H2O, dried over Na2SO4, filtrated and 
concentrated under vacuum to give the desired product. 
9a (S,aR): light orange oil; yield = 572 mg (1.09 mmol, 99 %) from 4a (734 
mg, 1.10 mmol); Rf = 0.1 (cyclohexane/AcOEt = 9/1); [α]D20 = -7.72 (c = 
1.05, CHCl3); ṽ = 2964.0, 2930.5, 2901.2, 1635.6 (C=N), 1440.0, 1415.1, 
1340.6 (C-O), 1205.3 (C-O), 1101.7, 1037.0, 970.6 cm-1; 1H NMR (CDCl3, 
400 MHz): δ = 7.26 (s, 1 H,  Ar-H), 7.22 (s, 1 H, Ar-H), 6.69 (s, 1 H, Ar-H), 
5.97 (s, 2 H, O-CH2-O), 4.09 (dd, 1 H, 3J  = 9.1 Hz, 2J  = 8.2 Hz, O-CH2-
C), 3.93 (s, 3 H, Ar-OCH3), 3.91 (s, 3 H, Ar-OCH3), 3.86 (ddd, 1 H, 3J = 9.1 
Hz, 3J = 8.2 Hz, 3J = 6.7 Hz, N-CH), 3.77 (dd, 1 H, 3J = 8.2 Hz, 2J = 8.2 Hz, 
O-CH2-C), 3.70 (s, 3 H, Ar-OCH3), 1.66 (sept.d, 1 H, 3J = 6.7 Hz, 3J = 6.7 
Hz, CHiPr), 0.86 (d, 3 H, 3J = 6.7 Hz, CH3iPr), 0.81 (d, 3 H, 3J = 6.7 Hz, 
CH3iPr) ppm; 13C NMR (CDCl3, 100 MHz): δ = 163.09 (CIV, C=N), 152.99 
(CIV, CAr), 151.36 (CIV, CAr), 147.70 (CIV, CAr), 147.38 (CIV, CAr), 144.33 (CIV, 
CAr), 135.99 (CIV, CAr), 131.97 (CIV, CAr), 123.61 (CIV, CAr), 117.63 (CHAr), 
110.53 (CHAr), 108.52 (CHAr), 101.58 (O-CH2-O), 89.70 (CIV, C-I), 72.61 
(N-CH), 70.42 (O-CH2-C), 61.11 (Ar-OCH3), 61.00 (Ar-OCH3), 56.15 (Ar-
OCH3), 32.78 (CHiPr), 18.95 (CH3iPr), 18.40 (CH3iPr) ppm; HRMS ES m/z 
[M+ Na]+ calcd. for C22H24INaNO6: 548.0546, found 548.0541. 
9b (S,aS): light yellow oil; yield = 440 mg (0.84 mmol, 99 %) from 4b (561 
mg, 0.84 mmol); Rf = 0.1 (cyclohexane/AcOEt = 9/1); [α]D20 = -5.60 (c = 
0.94, CHCl3); ṽ = 2963.0, 2928.5, 2900.2, 1633.6 (C=N), 1440.0, 1415.1, 
1340.6 (C-O), 1204.3 (C-O), 1100.7, 1036.0, 968.6 cm-1; 1H NMR (CDCl3, 
400 MHz): δ = 7.25 (s, 1 H,  Ar-H), 7.19 (s, 1 H, Ar-H), 6.76 (s, 1 H, Ar-H), 
5.97 (ABq, 2 H, ΔδAB = 0.01, JAB = 1.3 Hz, O-CH2-O), 4.15 (dd, 1 H, 3J  = 
8.7 Hz, 2J  = 7.3 Hz, O-CH2-C), 3.93 (s, 3 H, Ar-OCH3), 3.92 (s, 3 H, Ar-
OCH3), 3.91-3.84 (m, 1 H, N-CH), 3.82 (dd, 1 H, 3J = 7.8 Hz, 2J = 7.8 Hz, 
O-CH2-C), 3.68 (s, 3 H, Ar-OCH3), 1.62 (sept.d, 1 H, 3J = 6.7 Hz, 3J = 6.7 
Hz, CHiPr), 0.81 (d, 3 H, 3J = 6.7 Hz, CH3iPr), 0.80 (d, 3 H, 3J = 6.7 Hz, 
CH3iPr) ppm; 13C NMR (CDCl3, 100 MHz): δ = 162.93 (CIV, C=N), 152.96 
(CIV, CAr), 151.38 (CIV, CAr), 147.80 (CIV, CAr), 147.44 (CIV, CAr), 144.38 (CIV, 
CAr), 135.86 (CIV, CAr), 132.02 (CIV, CAr), 123.78 (CIV, CAr), 117.70 (CHAr), 
111.03 (CHAr), 108.44 (CHAr), 101.61(O-CH2-O), 89.31 (CIV, C-I), 72.80 (N-
CH), 70.41 (O-CH2-C), 61.05 (Ar-OCH3), 61.04 (Ar-OCH3), 56.14 (Ar-
OCH3), 32.98 (CHiPr), 18.85 (CH3iPr), 18.54  (CH3iPr) ppm. 
(aR)- and (aS)-[2-(6-iodo-2H-1,3-benzodioxol-5-yl)-3,4,5-
trimethoxyphenyl]methanol (12a and 12b) 
The desired atropo-diastereomer of 9 (1 equiv.) was dissolved in THF 
(0.12 M). Trifluoroacetic acid (5 equiv.) and water (50 equiv.) were then 
added and the mixture was stirred overnight at r.t. (LCMS monitoring). 
Saturated aqueous NaHCO3 was added portionwise to the stirred mixture 
until no more carbon dioxide evolution was observed and the mixture was 
extracted thrice with DCM. The combined organic layers were dried over 
Na2SO4, filtrated and concentrated under vacuum to give the crude amino-
ester intermediate that was then directly engaged into the reduction step. 
Under an argon atmosphere, a solution of borane-THF complex (1.2 equiv., 
1 M in THF) and methanol (5 equiv.) were added to a solution of the 
previous crude (1 equiv.) in dry THF (0.12 M). Lithium borohydride (5 
equiv.) was then added in one portion as a solid (CAUTION: hydrogen 
evolution). The mixture was refluxed for 1 h and quenched with 2 M HCl 
once cooled down (CAUTION: hydrogen evolution). Once there was no 
more hydrogen degassing, the mixture was extracted thrice with DCM. The 
organic layers were combined, dried over Na2SO4, filtrated and 
concentrated under vacuum. The crude was purified by flash 
chromatography on silica gel, eluting with a cyclohexane/AcOEt mixture, 
to give the purified alcohol as a colorless foam. 
12a (aR): yield = 255 mg (0.57 mmol, 91 %) from 9a (330 mg, 0.63 mmol; 
[α]D20 = +8.5 (c = 1, CH2Cl2) 
12b (aS): yield = 319 mg (0.72 mmol, 88 %) from 9b (430 mg, 0.82 mmol); 
[α]D20 = -8.8 (c = 1, CH2Cl2) 
Rf = 0.25 (cyclohexane/AcOEt = 6/4); ṽ = 3423.9 (O-H), 2934.6, 1598.0, 
1471.8, 1456.8, 1413.2, 1317.1, 1223.6, 1141.7, 1117.9, 1034.6, 1014.8, 
731.6, 556.1 (C-I) cm-1; 1H NMR (CDCl3, 400 MHz): δ = 7.33 (s, 1 H, Ar-
H), 6.91 (s, 1 H, Ar-H), 6.70 (s, 1 H, Ar-H), 6.01 (s, 2 H, O-CH2-O), 4.30 
(ABq, 2 H, ΔδAB = 0.06, JAB = 13.0 Hz, Ar-CH2-OH), 3.92 (s, 3 H, Ar-OCH3), 
3.89 (s, 3 H, Ar-OCH3), 3.73 (s, 3 H, Ar-OCH3), 1.73 (bs, 1 H, OH) ppm; 
13C NMR (CDCl3, 100 MHz): δ = 153.7 (CIV, CAr), 151.1 (CIV, CAr), 148.5 
(CIV, CAr), 148.0 (CIV, CAr), 141.5 (CIV, CAr), 135.0 (CIV, CAr), 134.5 (CIV, CAr), 
130.1 (CIV, CAr), 118.3 (CHAr), 110.7 (CHAr), 106.6 (CHAr), 101.9 (O-CH2-
O), 89.9 (CIV, C-I), 63.1 (Ar-CH2-OH), 61.1 (Ar-OCH3), 61.0 (Ar-OCH3), 
56.1 (Ar-OCH3) ppm; C17H17IO6 (444,01): calcd. C 45.97, H 3.86, found C 
45.57, H 3.99. 
(aR)- and (aS)-tert-butyl({[2-(6-iodo-2H-1,3-benzodioxol-5-yl)-3,4,5-
trimethoxyphenyl]meth-oxy})dimethylsilane (14a and 14b) 
Under an argon atmosphere, the desired atropo-enantiomer of 12 (1 
equiv.) was dissolved in dry DCM (0.1 M) and imidazole (2.5 equiv.) was 
added in one portion. Once dissolved, tert-butyldimethylsilyl chloride (1.2 
equiv.) was added in one portion and the mixture was stirred at RT for 5 
min. Saturated aqueous NH4Cl was added to the reaction mixture that was 
then extracted thrice with DCM. The organic layers were combined, dried 
over Na2SO4, filtrated and concentrated under vacuum. The crude product 
was purified by flash chromatography on silica gel, eluting with a 
cyclohexane/AcOEt mixture, to give the purified silylated alcohol as a 
colorless oil. The enantiomeric ratio of the product was determined by 
chiral HPLC on a Chiralpak IB column (hexane/isopropanol = 80/20; 0.5 
mL/min; tR = 8.00 min (aS), 8.78 min (aR)). 
14a (aR): yield = 293 mg (0.52 mmol, 99 %, e.r. > 99:1) from 12a (236 mg, 
0.53 mmol); [α]D20 = +15.0 (c = 1, CH2Cl2) 
14b (aS): yield = 350 mg (0.63 mmol, 87 %, e.r. > 99:1) from 12b (319 mg, 
0.72 mmol); [α]D20 = -15.3 (c = 1, CH2Cl2) 
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Rf = 0.25 (cyclohexane/AcOEt = 9/1); ṽ = 2930.1, 1598.6, 1472.4, 1457.3, 
1224.6, 1142.9, 1119.2, 1084.9, 1039.3, 1017.4, 836.2 (Si(CH3)3), 776.3 
(Si(CH3)3), 555.8 (C-I) cm-1; 1H NMR (CDCl3, 400 MHz): δ = 7.33 (s, 1 H, 
Ar-H), 6.98 (s, 1 H, Ar-H), 6.68 (s, 1 H, Ar-H), 6.02 (ABq, 2H, ΔδAB = 0.02, 
JAB = 1.1 Hz, O-CH2-O), 4.30 (ABq, 2H, ΔδAB = 0.08, JAB = 14.0 Hz, Ar-
CH2-OTBS), 3.92 (s, 3 H, Ar-OCH3), 3.88 (s, 3 H, Ar-OCH3), 3.73 (s, 3 H, 
Ar-OCH3), 0.92 (s, 9 H, C(CH3)3), 0.04 (s, 3 H, CH3), 0.02 (s, 3 H, CH3) 
ppm; 13C NMR (CDCl3, 100 MHz): δ = 153.44 (CIV, CAr), 150.83 (CIV, CAr), 
148.47 (CIV, CAr), 147.85 (CIV, CAr), 140.73 (CIV, CAr), 135.07 (CIV, CAr), 
134.98 (CIV, CAr), 128.64 (CIV, CAr), 118.32 (CHAr), 110.54 (CHAr), 105.20 
(CHAr), 101.86 (O-CH2-O), 89.66 (CIV, C-I), 62.74 (Ar-CH2-OTBS), 61.14 
(Ar-OCH3), 61.02 (Ar-OCH3), 55.92 (Ar-OCH3), 26.08 (C(CH3)3), 18.48 (CIV, 
C(CH3)3), -5.10 (Si-CH3), -5.15 (Si-CH3) ppm; C23H31IO6Si (558,09): calcd. 
C 49.46, H 5.60, found C 49.84, H 5.61. 
(aR)- and (aS)-6-(6-{[(tert-butyldimethylsilyl)oxy]methyl}-2,3,4-
trimethoxyphenyl)-2H-1,3-benzodioxole-5-carbaldehyde (3 and ent-3) 
Under an argon atmosphere, a solution of tert-butyllithium (5 equiv., 1.5 M 
in pentane) was added to dry THF (0.2 M) at -78 °C. This solution was 
cooled down to -100 °C after 10 min stirring. A solution of the desired 
atropoenantiomer of the silylated alcohol 14 (1 equiv.) in dry THF (0.2 M) 
was cooled down to -100 °C and was then cannulated onto the first one at 
-100 °C. The mixture was stirred for 10 min at this temperature before 
being quickly quenched with dry dimethylformamide (15 equiv.). The 
mixture was stirred for 30 min from -100 °C to RT. Saturated aqueous 
NH4Cl was added and the mixture was extracted thrice with Et2O. The 
organic layers were combined, washed thrice with water, dried over 
Na2SO4, filtrated and concentrated under vacuum. The crude was purified 
by flash chromatography on silica gel, eluting with a cyclohexane/AcOEt 
mixture, to give the purified aldehyde as a colorless oil. The enantiomeric 
ratio of the product was determined by chiral HPLC on a Chiralpak IB 
column (hexane/isopropanol = 95/5; 0.5 mL/min; tR = 11.40 min (aS), 11.94 
min (aR)). 
3a (aR): yield = 204 mg (0.44 mmol, 85 %, e.r. > 99:1) from 14a (290 mg, 
0.52 mmol); [α]D20 = - 2.8 (c = 1, CH2Cl2) 
3b (aS): yield = 166 mg (0.36 mmol, 81 %, e.r. > 99:1) from 14b (250 mg, 
0.45 mmol); [α]D20 = + 2.6 (c = 1, CH2Cl2) 
Rf = 0.12 (cyclohexane/AcOEt = 9/1); ṽ = 2930.8, 1682.5 (C=O), 1612.2, 
1598.2, 1475.4, 1462.3, 1239.5, 1139.0, 1102.0, 1058.8, 1035.4, 996.4, 
835.2 (Si(CH3)3), 776.7 (Si(CH3)3), 507.9 cm-1; 1H NMR (CDCl3, 400 MHz): 
δ = 9.50 (s, 1 H, CHO), 7.46 (s, 1 H, Ar-H), 6.96 (s, 1 H, Ar-H), 6.67 (s, 1 
H, Ar-H), 6.10 (ABq, 2 H, ΔδAB = 0.02, JAB = 0.9 Hz, O-CH2-O), 4.30 (ABq, 
2 H, ΔδAB = 0.09, JAB = 13.2 Hz, Ar-CH2-OTBS), 3.92 (s, 3 H, Ar-OCH3), 
3.87 (s, 3 H, Ar-OCH3), 3.61 (s, 3 H, Ar-OCH3), 0.87 (s, 9 H, C(CH3)3), -
0.03 (s, 3 H, CH3), -0.04 (s, 3 H, CH3) ppm; 13C NMR (CDCl3, 100 MHz): 
δ = 190.46 (CHO), 153.73 (CIV, CAr), 152.38 (CIV, CAr), 151.35 (CIV, CAr), 
148.05 (CIV, CAr), 140.90 (CIV, CAr), 137.20 (CIV, CAr), 135.54 (CIV, CAr), 
129.65 (CIV, CAr), 121.75 (CIV, CAr), 110.95 (CHAr), 106.39 (CHAr), 106.07 
(CHAr), 102.20 (O-CH2-O), 62.96 (Ar-CH2-OTBS), 61.06 (Ar-OCH3), 60.96 
(Ar-OCH3), 56.04 (Ar-OCH3), 25.98 (C(CH3)3), 18.42 (CIV, C(CH3)3), -5.29 
(Si-CH3), -5.33 (Si-CH3) ppm; HRMS ESI m/z [M+Na]+ calcd. for 
C24H32NaO7Si: 483.1815, found 483.1810. 
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